Startup Seigla Medical recently announced that it won CE mark approval for its LiquID guide catheter extension for use in coronary and peripheral vasculature interventions.
Guide catheter extensions are used by cardiologists to assist in the delivery of stents and other interventional devices, according to the Minneapolis-based company.
Seigla also announced that it completed the first PCI cases using the LiquID device.
“The LiquID’s exemplary support and flexibility were equally matched by the reassuring feeling of deliverability and ease of use,” Dr. Julian Strange, a doctor at the Bristol Heart Institute in the U.K. who performed three separate coronary procedures, said in a news release. “The design remit of unparalleled performance in complex coronary work has been fully realized in this world-leading guide catheter extension.”
The guide catheter extension allows doctors to safely extend their reach with a radio-dense, close-wound coil that illuminates the positioning of the atraumatic, rounded tip. Its bi-metal precision engineered coil is coated with conformable, ultra-thin polymer for a full-length radiopaque extension to the lesions that need to be treated. Its port also has a polymer leading edge that is half the thickness of competitive devices to minimize interactions with therapeutic devices to save space.
“The LiquID device is built on a proprietary and unique technical platform that miniaturizes device components, strengthens performance and provides significantly larger internal diameters. These attributes help interventionalists perform a wider array of challenging procedures in today’s world of complex intervention,” Seigla Medical president and CEO Chad Kugler said. “This technology is Seigla’s first product launch and is a precursor for the company to apply this platform to additional devices and additional clinical specialties.”
